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Enzyme replacement therapy administered during hemodialy-
sis in patients with Fabry disease.
Background. Enzyme replacement treatment with recombi-
nant human a-galactosidase A (r-haGalA) is now available for
patients with Fabry disease, many of whom are on maintenance
hemodialysis. Because r-haGalA must be infused over several
hours, administering the enzyme during dialysis would save a
day of treatment for patients receiving both therapies. However,
these procedures have never been combined due to concerns
about possible loss of enzyme in the dialysate.
Methods. Ten Fabry patients received r-haGalA (1 mg/kg
body weight continuously infused over 4 hours) during dial-
ysis and separately in the interval between dialysis treatments.
Plasma activity of r-haGalA was measured at baseline and
then every hour for both procedures. In two patients, a third
r-haGalA infusion during dialysis with a high-flux membrane
was followed.
Results. The rise in plasma concentrations of r-haGalA dur-
ing infusion and the steady-state levels reached were compa-
rable for enzyme administrations with or without dialysis. The
trend for the somewhat higher activities during hemodialysis
was explained by volume contraction due to ultrafiltration. With
the use of a high-flux dialyzer, the plasma r-haGalA activi-
ties were identical to those that were observed during low-flux
dialysis.
Conclusions. Administration of r-haGalA during hemodial-
ysis is not associated with a reduced activity of r-haGalA ther-
apy in patients with Fabry disease. Replacement therapy with
r-haGalA may therefore be performed during hemodialysis
without apparent loss of enzyme into the dialysate.
Fabry disease is a X-linked inherited lysosomal stor-
age disease caused by the deficiency of a-galactosidase
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A. The disease affects about 1 in 40,000 to 60,000 males;
however, carrier (heterozygous) females can also be af-
fected to a mild or severe degree depending on the pat-
tern of random X-chromosomal inactivation [1–3]. This
inborn error of glycosphingolipid catabolism leads to a
progressive accumulation of globotriaosylceramide and
related glycosphingolipids in vascular endothelial lyso-
somes of the kidneys, the heart, skin, and brain [1, 4].
Glycosphingolipid accumulation leads to vascular dam-
age, impairment of renal glomerular and tubular cells,
and chronic renal failure in affected males and some fe-
male carriers [4]. Progressive renal failure is the major
cause of morbidity and mortality in patients with Fabry
disease, who often require dialysis or transplantation by
the third or fourth decade of life [5, 6]. Although little
is known about the clinical characteristics of Fabry pa-
tients on dialysis, data from the European Registry sug-
gest that these patients have a poor survival once they
reach end-stage renal disease (ESRD) [7]. In addition to
renal disease, Fabry patients also experience serious dis-
ease manifestations in the heart, central nervous system,
and gastrointestinal tract [1, 4].
Specific treatment for Fabry disease is now available in
the form of enzyme replacement with r-haGalA [8–11].
In a randomized, placebo-controlled Phase 3 trial of 58
patients, Eng et al [8] showed that r-haGalA infusions
(1 mg/kg every two weeks for 20 weeks) resulted in stabi-
lization of renal function and almost complete clearance
of globotriaosylceramide from microvascular endothe-
lial deposits of the kidneys. Thurberg et al further eval-
uated skin, renal, and heart biopsy specimens obtained
during this trial and its six-month extension. They found
complete clearance of glycolipids from the endothelium,
from the mesangial cells of the glomerulus, and from in-
terstitial cells of the cortex, as well as significant reduc-
tion in globotriaosylceramide accumulation in podocytes
[12]. Studies with hard clinical end points investigating
effects of enzyme replacement therapy on morbidity and
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Table 1. Baseline characteristics of 10 patients with Fabry disease on
maintenance haemodialysis treatment
Parameter
Age years 45 ± 8.0
Male/female 10/0
BMI 21.4 ± 4.2
Blood pressure mm Hg 128 ± 9/72 ± 5
Time on dialysis years 5.7 ± 3.1
Ultrafiltration mL 1305 ± 82
mortality and a clear clinical benefit are missing so
far. However, given the histologically shown clearance
of globotriaosylceramide deposits from target tissues,
it appears conceivable that long-term treatment with r-
haGalA may prevent significant pathology in patients
with Fabry disease.
Infusion-associated, antibody-related reactions against
the recombinant protein make a relatively long infusion
time advisable [11], although these antibodies do not ap-
pear to alter the efficacy of r-haGalA. In patients on
maintenance hemodialysis, administering r-haGalA dur-
ing dialysis would save a day of treatment for the patient,
who would otherwise have to have a separate infusion in
the interval between dialysis treatments. However, com-
bining these treatments has not been attempted due to
concerns about the effect of hemodialysis treatment on
the pharmacokinetics of the drug (i.e., possible loss of
enzyme in the dialysate). We thus compared the plasma
activity of r-haGalA infused during hemodialysis and
infused separately. Moreover, we studied a possible in-
fluence of different dialyzer membranes—high-flux ver-
sus low-flux membranes—on the plasma activity of the
enzyme.
METHODS
This study was performed in accordance with the eth-
ical standards laid down in the updated relevant ver-
sion of Declaration of Helsinki and approved by the
medical ethics committee at the Westfa¨lische Wilhelms-
University, Mu¨nster, Germany. All patients gave their in-
formed consent. Eligible patients were between 18 and
65 years of age and were on maintenance hemodialysis
treatment for end-stage renal insufficiency due to Fabry
disease. All patients had an enzymatically confirmed di-
agnosis of classic Fabry disease. Ten male Caucasian
patients from centers in Germany, Denmark, Italy, and
Portugal were enrolled in the study. Baseline character-
istics of the patients are given in Table 1.
Patients received r-haGalA (agalsidase beta;
Fabrazyme, Genzyme, Cambridge, MA, USA) at
a dose of 1 mg/kg body weight in 500 mL NaCl 0.9%
solution intravenously at a rate of 125 mL/hr. No
pretreatment was administered because all patients had
tolerated infusion of r-haGalA before. Infusions were
performed either during hemodialysis with the infusion
started 15 minutes after the start of hemodialysis, or
separately during the interval between dialysis sessions.
Patients were randomized to the sequence of treatments.
The plasma activity of r-haGalA activity was measured
at baseline and at hourly intervals thereafter.
In two patients, the influence of different dialyzer mem-
branes was tested by measuring the plasma activity of
r-haGalA activity during hemodialysis with either a low-
flux polysulphone dialyzer (F8 HPS, surface area 1.6 m2,
steam-sterilized; Fresenius, Bad Homburg, Germany) or
a high-flux polyamide dialysis filter (Polyflux 14L, sur-
face area 1.4 m2, steam-sterilized; Gambro, Hechingen,
Germany). Patients were randomly assigned to dialysis
with one dialyzer, and were crossed over to the other
membrane the next dialysis session.
Activity of a-galactosidase A in plasma was de-
termined according to Desnick et al [13] using
4-methylumbeliferyl-alpha-D-galactopyranoside (4MU-
Gal) as substrate and N-acetyl-D-galactosamine
(GalNAc) as inhibitor of a-galactosidase B (Sigma
Chemical Co, St. Louis, MO, USA). 4MU-Gal
(5 mmol/L), 117 mmol/L GalNAc in citrate/phosphate
buffer, ph 4.6 (150 lL) and plasma sample (25 lL)
were incubated at 37◦C for 1 hour, quenched with
ethylenediamine solution, and the fluorescence signals
were measured at excitation 360 nm/emission 450 nm.
Activity of a-galactosidase A can be given as lmol/h/mL
or as U/mL. A unit (U) was estimated as a-galactosidase
A activity capable of hydrolyzing 1 nmol of substrate
per hour at 37◦C. Using this assay, the lower cut-off of
a-galactosidase A activity in plasma for healthy male
adults (N = 58) was 2.2 U/mL. Male (hemizygous)
Fabry’s disease patients (N = 10) revealed 0.04 to 0.84
U/mL. Plasma samples were measured immediately
after collection, and each analysis was performed in
duplicate. Each assay was run with an internal standard.
Statistics
Data are expressed as mean ± standard error of the
mean (SEM). The effect of hemodialysis treatment on
plasma activity of r-haGalA activity was tested by re-
peated measures analysis of variance (ANOVA) and
post-hoc comparisons (planned contrasts). Influence of
blood pressure and ultrafiltration volume on changes of
plasma activity of r-haGalA was tested by analysis of co-
variance. Statistical significance was assumed at P < 0.05.
RESULTS
The rise in plasma concentrations during r-haGalA
infusion and the steady-state levels reached were com-
parable for enzyme administrations with or without
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Fig. 1. Rise of plasma a-galactosidase A activity and steady-state levels
reached by enzyme administrations during hemodialysis or separate
infusions in the interval between dialysis sessions.
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Fig. 2. a-galactosidase A activity during enzyme administrations dur-
ing hemodialysis with either a high-flux dialyzer (Polyflux 14L, Gambro)
or a low-flux dialyzer (F8 HPS, Fresenius).
hemodialysis (Fig. 1). There was a trend for higher
r-haGalA activities during hemodialysis that reached
statistical significance after 180 minutes infusion of
r-haGalA (P < 0.05). Analysis of covariance revealed
that increase in r-haGalA activitiy after 2 hours of infu-
sion during dialysis compared to infusion without dialysis
was independent of blood pressure (P = 0.72), but was
significantly related to increase in ultrafiltration volume
(P < 0.05). Thus, the trend to higher r-haGalA activi-
ties after 120 minutes of infusion during dialysis can be
explained by volume contraction due to ultrafiltration.
In the two patients in which r-haGalA activity was fol-
lowed during hemodialysis with either a high-flux dialyzer
or a low-flux dialyzer, plasma r-haGalA activities were
comparable (Fig. 2), suggesting no influence of the tested
filter membranes.
DISCUSSION
In addition to renal disease, Fabry patients are at risk of
cardiovascular complications such as left ventricular hy-
pertrophy and valvular disease, cerebrovascular manifes-
tations such as early stroke and transient ischemic attacks,
and gastrointestinal disturbances such as chronic diarrhea
[1, 11]. Although enzyme replacement therapy is unlikely
to reverse severe renal impairment or improve end-stage
renal disease, the therapeutic goal of halting disease pro-
gression in other organs, such as the heart, central ner-
vous system, cerebrovascular system, and gastrointestinal
tract justifies therapy in hemodialysis patients. Moreover,
recent studies demonstrate that cerebral perfusion ab-
normalities observed in Fabry patients are reversible by
enzyme replacement therapy [14, 15]. However, it has to
be emphasized that data from studies investigating possi-
ble effects of enzyme replacement therapy on morbidity
and mortality using hard clinical end points are still miss-
ing. Therefore, a clear clinical benefit of therapy has not
been shown yet, and treatment is generally justified by the
studies on histologic clearance of globotriaosylceramide
deposits from target tissues.
Because Fabry disease is so rare and can be difficult to
identify, many patients are missed or misdiagnosed. Stud-
ies in other populations [2, 16] suggest that in Germany
alone, there may be up to 1000 patients with Fabry dis-
ease, although only a few dozen are regularly treated so
far. Thus, enzyme replacement therapy in patients with or
without dialysis may become more common in the future
as more patients are recognized.
With a recommended infusion rate of 15 mg/hr and
a dosage of 1 mg/kg body weight, the infusion time
for r-haGalA can be more than four hours. In patients
with end-stage renal disease who must undergo chronic
hemodialysis, it would therefore be advantageous to in-
fuse the enzyme during dialysis. Infusion during dialysis is
unlikely to affect the safety or toleration of the treatment;
moreover, safety or efficacy measures were beyond the
scope of our study. However, combining both treatments
can save the patient a day of therapy and reduce costs
and inconvenience. Our data show that the hemodialysis
procedure, per se—independent of the tested dialyzers
used—does not appear to alter activity of the infused en-
zyme during replacement therapy in Fabry patients.
The molecular weight of r-haGalA is approximately
120,000 daltons and the cut-off of high flux-membranes is
near 60,000 daltons; thus, the fact that no enzyme loss was
observed is plausible. Moreover, the somewhat higher
plasma r-haGalA activity that results from volume con-
traction due to ultrafiltration may be even advantageous,
and enhance the transfer of the enzyme to target tissues.
However, to determine if the higher r-haGalA activity
during infusion due to ultrafiltration is clinically mean-
ingful is beyond the scope of our study.
Some limitations must be noted when interpreting our
data. First, due to the very low prevalence of the disease,
our study included relatively few patients, especially in
the comparison of high-flux and low-flux filters. Further
studies may be needed to confirm our data. Second, we
did not study the efficacy of enzyme replacement (e.g.,
by evaluating clearance of globotriaosylceramide from
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target tissues). Our study was designed only to investi-
gate potential effects of hemodialysis on plasma activity
of the infused r-haGalA. Whether enzyme replacement
therapy is efficacious in patients with end-stage renal dis-
ease and is of clinical benefit remains to be elucidated
by larger long-term studies with clinical end points. Fi-
nally, we studied only patients on enzyme replacement
therapy with agalsidase beta, one of two compounds
that are approved for treating patients with Fabry dis-
ease. Although the molecular weights of both human
a-galactosidase A molecules—agalsidase beta and
agalsidase alfa (ReplagalTM; Transkaryotic Therapies,
Cambridge, MA, USA)—are rather similar, further stud-
ies are needed to decide whether our data is confirmed
for enzyme replacement therapy with agalsidase alfa.
CONCLUSION
Our study suggests that administration of enzyme re-
placement therapy with r-haGalA during hemodialysis
is not associated with a reduced activity of the infused
enzyme or an apparent loss into the dialysate in patients
with Fabry disease.
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